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Abstract—Silver nanoparticles (Ag-nps) are currently used as
a natural biocide to prevent undesired bacterial growth in
clothing, cosmetics and medical products. The objective of
the study was to impart antibacterial properties through the
incorporation of Ag-nps at increasing concentrations to
electrospun degradable 50:50 poly(L-lactide-co-epsilon-
caprolactone) scaffolds for skin tissue engineering applica-
tions. The biocompatibility of the scaffolds containing Ag-
nps was evaluated with human epidermal keratinocytes
(HEK); cell viability and proliferation were evaluated using
Live/Dead and alamarBlue viability assays following 7 and
14 days of cell culture on the scaffolds. Significant decreases
in cell viability and proliferation were noted for the
1.0 mg(Ag) g(scaffold)21 after 7 and 14 days on Ag-nps
scaffolds. After 14 days, scanning electron microscopy
revealed a confluent layer of HEK on the surface of the 0.0
and 0.1 mg(Ag) g(scaffold)21. Both 0.5 and 1.0 mg(Ag)
g(scaffold)21 were capable of inhibiting both Gram positive
and negative bacterial strains. Uniaxial tensile tests revealed
a significant (p< 0.001) decrease in the modulus of elasticity
following Ag-nps incorporation compared to control. These
findings suggest that a scaffold containing between 0.5 and
1.0 mg(Ag) g(scaffold)21 is both biocompatible and antibac-
terial, and is suitable for skin tissue engineering graft
scaffolds.
Keywords—Nanoparticle, Keratinocyte, Skin tissue engineer-
ing, Scaffold, Biocompatibility.
INTRODUCTION
The skin, the largest organ of the body, performs
numerous vital functions, including fluid homeostasis,
thermoregulation, immunologic functions, neurosen-
sory functions, and metabolic functions such as vita-
min D synthesis. The skin also provides primary
protection against infection by acting as a physical
barrier, and when this barrier is damaged pathogens
have a direct route to infiltrate the body, possibly
resulting in infection.23 Annually, over 2 million
wounds in the United States alone require advanced
care; the major etiologies of these complex wounds
include venous, diabetic and pressure ulcers, burns,
amputations and trauma.9 Dermatomed, meshed skin
grafts, and micrografting of autologous donor skin is
efficient for closing large wounds, but results in the
creation of additional partial thickness wounds that
also need to heal. Alternatively, biological membranes
such as cadaver skin, pig skin, and neonatal skin
substitutes provide temporary coverage, but are hin-
dered by limited supply and immunological complica-
tions.3 Despite great advances in skin wound care,
severe scarring and deformity is one of the greatest
challenges facing patients with skin lesions.
The field of tissue engineering and regenerative
medicine with its mission to ‘‘develop biological sub-
stitutes that restore, maintain, or improve tissue
function’’ has been revolutionary in terms of
attempting to resolve these shortcomings.17 Skin tissue
regeneration may be achieved through the use of a
degradable synthetic membrane on which a patient’s
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cells may be seeded. In contrast to conventional
grafting, in which autologous donor skin expansion is
limited to approximately 1:4 by meshing and micro-
grafting procedures, the rapid growth of patient-
derived cells in vitro can provide in excess of 60 times
the area of the initial biopsy. In this method, cells
isolated from patient biopsies as small as 4 square
inches can be expanded to cover catastrophic burns
covering over 80% of the body in about 2 months.2
The requirements for suitable tissue engineering scaf-
folds are demanding and extensive. More specific
requirements are necessary on a per tissue basis; for
example, skin replacements are required to be bacte-
riostatic, semi-permeable to water, and cosmetically
acceptable.30 Skin scaffolds should also be elastic enough
to withstand cyclic mechanical strains without any
significant permanent deformation or creep.5,14,15
In the past, tissue scaffolds have been fabricated
from synthetic products or from acellular matrices
sourced from human tissues. More recently, polymers
such as poly(L-lactide) (PLA), poly(glycolic acid)
(PGA), poly(e-caprolactone) (PCL), as well as hydro-
lyzable and biocompatible copolymers of PLA and
PCL (poly(L-lactide-co-epsilon-caprolactone); PLCL)
have been used to fabricate successful tissue engineered
scaffolds for various soft tissues.6,7,10,12,16,21 Compared
to other bioresorbable polymers such as PGA and
PLA, the PLCL copolymer has a slow rate of degra-
dation, with in vivo studies reporting 81 mass%
retained after 15 weeks of implantation.14 Scaffolds
may be fabricated using an array of different tech-
niques; however, electrospun nanofibrous polymer
scaffolds are increasingly being favored since they
provide a three-dimensional structure similar to the
natural environment and are easily tailored to provide
the necessary requirements such as mechanical prop-
erties, surface topography and chemistry, and in vivo
degradation rate.10,12,20,25 This enables the fabrication
of a structure resembling the extracellular matrix with
a high surface area to volume ratio.
Infection risks are a danger in any surgical tech-
nique, and tissue engineered constructs risk contami-
nation during the in vitro culture step and also during
implantation. To address this unresolved problem,
silver nanoparticles (Ag-nps) have been incorporated
into several different medical devices due to their
ability to exert antibacterial effects against a both
Gram-positive and Gram-negative bacteria, as well as
multidrug-resistant strains with limited toxicity.27,28
Very few Ag-nps electrospun scaffolds have been
developed; however, they have taken the approach of
loading AgNO3 into the polymer solution and then
exposing the scaffold to an annealing process to reduce
the precursor into Ag-nps.13,18 While this process
negates complications involving particle agglomeration
upon introduction into the polymer solvent, the
reduction process can produce a large range in particle
sizes and particle attachment location.
The objective of this study was to characterize and
assess the biocompatibility of an electrospun scaffold
of PLCL nanofibers incorporating antibacterial 20 nm
Ag-nps. Since this type of resorbable scaffold has
potential applications in the regeneration of skin tis-
sue, this study included an evaluation of the mechan-
ical properties, attachment and proliferation of human
epidermal keratinocytes (HEK), the level of antimi-
crobial activity promoted by the slow release of the
silver from the degrading polymer matrix.
MATERIALS AND METHODS
Synthesis and Characterization of Ag-nps
The 20 nm Ag-nps (1.00 mg mL21) were obtained
from NanoComposix (San Diego, CA, USA). Ag-nps
were synthesized by ammonium hydroxide catalyzed
growth of Ag onto 5 nm gold seed particles while in
the presence of citric acid. According to the manu-
facturer, following synthesis the Ag-nps were concen-
trated via tangential flow filtration, serially washed and
suspended in deionized (DI) water and 2 mM citrate
buffer. Upon arrival, the Ag-nps were stored at 4 C in
the dark.
Particle size and surface characterization was
determined by dynamic light scattering (DLS) and
transmission electron microscopy (TEM) to confirm
the manufacturer-identified diameters and surface
characterization. Ag-nps were suspended at the highest
dosing concentration of 100 lg mL21 in deionized
(DI) water, Mueller–Hinton bacterial broth, and
KGM-2 cell culture medium. Immediately after dis-
persion, the Ag-nps were placed in a disposable cuvette
and DLS measurements were carried out on a Zeta-
sizer Nano-ZS (Malvern Instruments, Inc., Worces-
tershire, UK). The initial DLS readings were
performed at the standard characterization tempera-
ture of 25 C. Each measurement was repeated five
times, with 10–20 runs per measurement; data was
culled based on the correlogram and size quality report
rendered by the Dispersion Technology Software
(5.03). Additionally, TEM was utilized to characterize
the structure, shape and size uniformity of the Ag-nps.
Specimens were prepared by placing 10 lL of homo-
geneous suspension of Ag-nps at the highest dosing
concentration in DI water onto formvar-coated copper
mesh grids and air dried. Then, the grids were exam-
ined on an FEI/Philips EM 208S TEM operating at an
accelerating voltage of 80 kV.
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Poly(lactide-co-epsilon-caprolactone) (PLCL)
Copolymer
The PLCL copolymer was created using L-lactide
(100 mmol), e-caprolactone (100 mmol), and 1,6-hex-
anediol (0.5 mmol), which were polymerized at 150 C
for 24 h, using stannous octoate (1 mmol) as a cata-
lyst. After the reaction, the product was dissolved in
chloroform and precipitated in methanol, filtered and
dried under vacuum. The molar ratio of the two syn-
thetic monomers (PLA and PCL) in the PLCL
copolymer was 50:50). The average molecular weight
of the copolymer was MW = 350,000. The bulk
copolymer was stored in sealed plastic bags in a vac-
uum desiccator.
Solution Preparation
The solvent used for dissolving the polymer was
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP; Sigma-
Aldrich, USA). Based on a previous study performed
in our lab,5 the optimal electrospinning polymer con-
centration of 11% (w/v) was prepared. Homogeneous
solutions were obtained by slow agitation with a
magnetic stirrer at 300 rpm for 3 h. The polymer was
readily dissolved at room temperature, and the solu-
tion remained stable during storage at room tempera-
ture for up to 7 days prior to electrospinning. Control
polymer solutions were prepared without Ag-nps, and
were observed to be clear in appearance.
It was noted that direct addition of Ag-nps into the
polymer solution caused particle agglomeration; in
order to overcome this problem, prior to Ag-nps
addition into the polymer solution, the desired quan-
tity of Ag-nps were first spun down at 16,000 g to form
a soft pellet, the water was removed, and the pellet was
resuspended into HFIP. Each of the resuspended
Ag-nps samples were added to a concentrated polymer
solution in order to yield the optimal 11% (w/v)
polymer concentration. In this experiment, the Ag-nps
samples were added to the polymer solution at a con-
centration of 0.5 mg Ag-nps (0.5 mL of 1 mg mL21
Ag-nps stock solution, spun down, and water
removed) to give a total polymer volume of 15 mL.
Using inductively-coupled plasma mass spectroscopy
(ICP-MS), the resulting scaffolds were shown to con-
tain 0.11 ± 0.01 mg(Ag) g(scaffold)21. To increase the
Ag content of the scaffolds in later experiments, the
concentration of the Ag added to the scaffolds was
raised by 5 and 10 times the original concentration.
The higher concentrations of 0.5 and 1.0 mg Ag-nps
(2.5 and 5.0 mL of 1 mg mL21 Ag-nps stock solution,
spun down, and water removed) yielded scaffolds with
approximately 0.5 and 1.0 mg(Ag) g(scaffold)21. Each
polymer solution produced 2 in 9 2 in scaffolds
(n = 4). All scaffolds were sterilized by ethylene oxide
prior to use.
Electrospinning
The custom designed electrospinning apparatus
consisted of a high-voltage power supply (Gamma
High Voltage Research, Inc), an infusion pump (New
Era Pump System, Inc), a 15 mL plastic syringe, a
stainless steel blunt-ended needle (20 gauge) and a
15 cm diameter metal collector. The syringe was
mounted horizontally on the infusion pump and the
sample solution was fed at a constant rate through the
syringe to the needle tip. The distance between the
needle tip and the collector was maintained at 15 cm.
The applied voltage to the needle tip was 7.5–10 kV
and the flow rate of the solution was 1.0 mL h21.
Control PLCL polymer films were electrospun without
Ag-nps. Electrospun scaffolds were collected and the
centermost area (4 in 9 4 in) was used for all testing.
Fiber Characterization
In order to determine the morphology and diameter
of the filaments, the scaffolds were viewed using TEM
and scanning electron microscopy (SEM). SEM images
were acquired from a JEOL JSM 6360LV SEM using
an accelerating voltage of 5 kV. Specimens were
mounted on aluminum stubs with conductive carbon
tape and then sputter coated with gold/palladium
using a HummerTM 6.2 Sputter Coating System
(Anatech, CA, USA) to obtain a conductive coating
about 100 Å thick. SEM images of the control and
Ag-nps PLCL webs were used to measure the mean
fiber diameters. Using ImagePro software, fiber
diameters were measured on 100 randomly selected
fibers from each individual SEM image. Furthermore,
TEM was utilized to confirm the incorporation of Ag-
nps within the fibers; copper mesh grids were mounted
on the electrospinning collector and the polymer was
allowed to spin onto their surface. Grids were then
examined on an FEI/Philips EM 208S TEM operating
at an accelerating voltage of 80 kV.
Biocompatibility Analysis
Cryopreserved primary neonatal HEK (Lonza,
Walkersville, MD) were grown in keratinocyte growth
medium-2 (KGM-2; Lonza, Walkersville, MD) in cell
culture flasks (75 cm2; 1,000,000 cells) to approxi-
mately 80% confluency in a 37 C humidified 5% CO2
incubator. Cells were then passed into cell culture
plates for biocompatibility testing. For initial toxicity
testing of the Ag-nps, HEK were passed into black
96-well microplates (12,500 cells/well; 200 lL) in
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which the peripheral wells contained only KGM-2 to
prevent the evaporation of treatment medium.
Between 18 and 24 h later, after reaching approxi-
mately 80% confluency, HEK were exposed for 24 h to
either KGM-2 (control) or serial dilutions of Ag-nps
starting at 100 lg mL21. The viability of the HEK was
assessed using alamarBlue (aB) viability assay; aB
viability assay was used because it was determined to
be the best viability assay for examining the toxicity of
Ag-nps.26 The fluorescent values of treated cells were
normalized to the control cells, and the data expressed
as percentage viability.22
For biocompatibility testing of the scaffolds, control
and Ag-nps PLCL webs were first soaked in KGM-2
medium overnight prior to cell seeding to facilitate
protein adsorption and cell attachment onto the fiber
surface. Cells were seeded onto the control and
Ag-incorporated scaffolds (1 in 9 1 in) in 6-well plates
(50,000 cells per well; 2 mL), and the medium was re-
freshed every other day. After 7 and 14 days, the aB
assay was used to determine cell proliferation within
the scaffolding, compared to cells grown as a mono-
layer in an identical area. Live/Dead viability assay
was also used to determine the viability of HEK on the
scaffolds and visualize cell attachment, as determined
by the percentage of cells that fluoresced green.
Cell attachment and proliferation within the scaf-
fold was also observed using SEM. Images were
acquired from a JEOL JSM-6360LV SEM using an
accelerating voltage of 5 kV. After cell incubation at 7
and 14 days, scaffolds were fixed with Trump’s fixative
for 24 h. Then, they were rinsed with 0.1 M phosphate
buffer (pH 7.2), followed by deionized water, and then
dehydrated by processing through an ascending series
of aqueous ethanol solutions. The scaffolds were then
submersed in hexamethyldisilazane overnight, sputter
coated as described above, and then observed by SEM.
Degradation
Papain enzyme was used to simulate an accelerated
in vivo enzymatic environment.5,20 The papain enzyme
solution was activated prior to the start of the degra-
dation study by adding 0.01 M EDTA solution with
0.05 M of cysteine, papain from papaya latex (Sigma
Aldrich, USA), 0.01 M ethylenediaminetetraacetic
acid (EDTA) (Sigma Aldrich, USA), and 0.05 M
L-cysteine hydrochloride monohydrate (Sigma Aldrich,
USA). The activated solution was prepared based on
the mole ratio of 1: 2.5: 12.5 between enzyme, EDTA,
and cysteine respectively. In order to maintain the
activity of the enzyme during the entire degradation
period, the enzyme solutions were replenished
with activated enzymes after every 72 h. Scaffolds
(1 in 9 1 in) were subjected to the degradation
solution for 7 days at 37 C. The mass of dry scaffolds
was measured before and after the degradation treat-
ment. Additionally, ICP-MS was used to confirm the
linearity of Ag release during scaffold degradation.
Antibacterial Efficacy
Cation-adjusted Mueller–Hinton (MH) broth and
agar (Difco Laboratories, Detroit, MI) was used as the
bacterial cultivating medium for Escherichia coli
MG1655 and Staphylococcus aureus (ATCC 25213).
Isolated bacterial colonies were grown overnight at
37 C from frozen samples on an agar plate. The broth
microdilution minimum inhibitory concentration
(MIC) test was conducted to measure the in vitro
activity of Ag-nps against each bacterial isolate.29
Briefly, a sterile round-bottom plastic 96-well plate was
loaded with 100 lL of serially 1:2 diluted concentra-
tions of Ag-nps. Ag-nps samples were tested at ten
serially diluted concentrations starting at the highest
dosing concentration that their supplied concentra-
tions would allow (1.00 mg mL21). Silver nitrate
(AgNO3; 99.9%, Sigma-Aldrich, St. Louis, MO) was
used as the positive control source of Ag+ ions. For
each bacterial strain, a bacterial colony was suspended
into phosphate buffered saline (PBS) to 0.5 McFarland
(108 CFU/mL), diluted 1:20 into MH broth, and added
into the treatment wells at 100 lL of 5–8 9 105 CFU/
mL (n = 8 wells/treatment). To ensure quality control
and for seeding accuracy, inoculating bacteria were
diluted in PBS at 103, 104, 105, and 106 and plated
overnight. Microplates were incubated at 37 C and
shaken at 200 rpm for 24 h. After the microplates were
incubated for 24 h at 37 C, the lowest concentration
showing no visible growth was recorded as the MIC.
To determine the MBC, 10 lL from all of the clear
wells (MIC and higher concentrations) was dropped
onto a MH agar plate and incubated for 24 h at 37 C.
The minimum bactericidal concentration (MBC) was
determined by the concentration that failed to yield
growth.
To assess the antibacterial efficacy of the Ag incor-
porated scaffolds, 100 lL of the degradation solution
from each scaffold was plated onto bacterial lawns and
allowed to grow overnight. To prevent agar degrada-
tion, the degradation solution was briefly heated to
100 C to inactivate remaining papain and then cooled
prior to plating. Any bacterial inhibition caused by the
released Ag was recorded.
Tensile Testing
The mechanical properties of the PLCL scaffolds
was assessed via uniaxial tensile testing to failure at a
cross-head speed of 0.5 mm/s, during which force and
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displacement data as well as videos were recorded, as
well as video recording of the gauge length over time
(n = 4 for each group). All specimens were prepared
by punching into dog-bone shaped specimens using a
die with a gauge length of 20 and 5 mm. Naked scaf-
folds were tested ‘‘as is,’’ while 14 days cell growth
scaffolds and 7 days degraded scaffolds were trans-
ferred directly from their cell culture plates to a board
where they were lightly blotted, punched, and imme-
diately tested. Specimens were mounted between
pneumatic grips with a 250 g load cell mounted under
the bottom fixed grip. Acellular and 14 days cell
growth control scaffolds were tested using an Elec-
troForce (Bose, Minnesota, USA) mechanical system,
but malfunction of the system required all other
specimens to be tested using a Mini-Bionix II
mechanical testing machine (MTS, Minnesota, USA).
The load cell and all other test conditions were main-
tained. The modulus of elasticity was calculated from
the slope of the linear portion of the standard stress–
strain curves. The strain was calculated from the
recorded videos using ImagePro software to track the
movement of dots drawn onto the scaffold gauge
length.
Statistical Analysis
The mean values for fiber diameter, HEK percent
viability (Live/Dead assay), and MIC/MBC values
were calculated, and the significant differences between
the means (p< 0.05) were determined by the PROC
GLM Procedure (SAS 9.1 for Windows; SAS Institute,
Cary, NC); significant differences between the mean
values for proliferation (aB assay; normalized to con-
trol cells grown as a monolayer) and modulus of
elasticity were analyzed by two-way ANOVA with
respect to Ag content and cellular or degradation
treatment. For all analyses, when significant
differences were found, multiple comparisons were
performed using Tukey’s Studentized Range High
Standard Deviation test at p< 0.05 level of signifi-
cance. The data were expressed as the mean ± stan-
dard error of the mean (SEM) for n = 6.
RESULTS
Cytotoxicity
As the concentration of the 20 nm Ag-nps
increased, there was no significant decrease in HEK
viability following 24 h exposure until 50 lg mL21,
and at 100 lg mL21 there was nearly a complete loss
of viability (Fig. 1).
Fiber and Ag-nps Morphology
The physicochemical properties of the 20 nm Ag-nps
can be found in Table 1, which lists their physical and
hydrodynamic diameters according to TEM and DLS,
respectively, as well as the supplied Ag-nps solution
concentration, particle concentration, and zeta
potential. As is typical for nanoparticles, the hydrody-
namic diameter of the 20 nm Ag-nps measured by DLS
was slightly larger (27.4 nm) than the physical diameter
measured by TEM (19.2 nm). The significantly larger
hydrodynamic diameter is most likely attributable to the
formation of small, loosely bound Ag-nps dimers.
Agglomeration of Ag-nps occurred after incorporation
into MH broth (659.3 ± 30.7) and KGM-2 medium
(2721.5 ± 178.3) which is consistent with the previously
reported behavior of nanoparticles which are known to
physically interact with proteins and promote agglom-
eration.22,23,26 The zeta potential of a colloid suspension
characterizes its stability and ability to resist aggrega-
tion, with greater zeta potentials having greater stabil-
ity. The 20 nm Ag-nps suspension had a zeta-potential
FIGURE 1. HEK viability after 24 h exposure to 20 nm Ag-nps. Different letters denote statistical significance (p < 0.05) between
concentrations.
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of 250 eV which indicates good stability due most
likely to the stabilizing effect of the citrate buffer. Based
on TEM evaluation, the 20 nm Ag-nps were spherical in
shape and highly uniform in size both before and after
incorporation into the PLCL fibers (Figs. 2a–2d). It was
noted that at the lowest concentration of incorporation
that small agglomerates were interspersed throughout
the fibers (Fig. 2b), at 0.5 mg(Ag) g(scaffold)21 the
Ag-nps were highly monodisperse (Fig. 2c), and at the
highest concentration the Ag-nps appeared to align
within the fibers (Fig. 2d).
By visual observation, control PLCL scaffold
appeared white whereas Ag-np incorporated PLCL
scaffolds appeared increasingly grey with increasing
concentration. The morphology of the obtained PLCL
fibers was observed using SEM. Figures 3a–3l show
selected SEM images of control and Ag-nps PLCL
webs before and after HEK cell culture for 7 and
14 days. Smooth, connected fibers were observed in
Figs. 3c, 3d, 3h and 3l as well as fiber agglomeration in
Figs. 3a, 3b, 3e and 3f, which is indicative of incom-
plete solvent evaporation. No significant difference in
FIGURE 2. Transmission electron micrographs of Ag-nps and Ag-nps incorporated PLCL scaffolds. (a) 20 nm Ag-nps,
Bar 5 50 nm; (b) 0.1 mg(Ag) g(scaffold)21, Bar 5 0.5 lm; (c) 0.5 mg(Ag) g(scaffold)21, Bar 5 0.5 lm; (d) 1.0 mg(Ag) g(scaffold)21,
Bar 5 0.5 lm.



















20 27.4 ± 0.2 2721.5 ± 178.3 659.3 ± 30.7 19.2 ± 2.2 1.00 2.6 9 1013 249.8 ± 0.5
Data are expressed as mean ± standard error of the mean; a DI water, b KGM-2 medium, c MH broth; MDD, manufacturer-designated
diameter; DLS, dynamic light scattering; TEM, transmission electron microscopy.
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average fiber diameters (p< 0.05) was noted between
the control, 0.1 and 0.5 mg Ag/g scaffolds; the average
diameter for the control PLCL web was
2.25 lm ± 0.18 lm, while the average fiber diameter
for the 0.1 and 0.5 mg Ag/g scaffold webs were
2.70 lm ± 0.19 lm and 2.54 lm ± 0.78 lm, respec-
tively. However, the 1.0 mg Ag/g scaffold web had a
significantly increased (p< 0.05) average diameter of
3.96 lm ± 0.36 lm.
Biocompatibility
SEM images depicted the attachment and prolifer-
ation of HEK on both control and Ag-nps PLCL
samples throughout their 7 and 14 days time period of
cell culture, exhibiting characteristic HEK morphology
(Figs. 3e–3l). Following 7 days of incubation, indi-
vidual HEK were easily observed on both the control
and each of the Ag-np incorporated PLCL webs
FIGURE 3. Scanning electron micrographs of PLCL webs before and after 7 and 14 days growth of HEK. (a) 0.0 mg(Ag) g(scaf-
fold)21 PLCL, 0 days, Bar 5 10 lm; (b) 0.1 mg(Ag) g(scaffold)21, 0 days, Bar 5 10 lm; (c) 0.5 mg(Ag) g(scaffold)21, 0 days,
Bar 5 10 lm; (d) 1.0 mg(Ag) g(scaffold)21, 0 days, Bar 5 10 lm; (e) 0.0 mg(Ag) g(scaffold)21, 7 days, Bar 5 10 lm; (f) 0.1 mg(Ag)
g(scaffold)21, 7 days, Bar 5 10 lm; (g) 0.5 mg(Ag) g(scaffold)21, 7 days, Bar 5 50 lm; (h) 1.0 mg(Ag) g(scaffold)21, 7 days,
Bar 5 50 lm; (i) 0.0 mg(Ag) g(scaffold)21, 14 days, Bar 5 20 lm; (j) 0.1 mg(Ag) g(scaffold)21, 14 days, Bar 5 10 lm; (k) 0.5 mg(Ag)
g(scaffold)21, 14 days, Bar 5 50 lm; (l) 1.0 mg(Ag) g(scaffold)21, 14 days, Bar 5 50 lm. Arrows denote HEK cells.
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(Figs. 3e–3h). After 14 days, the HEK were able to
form confluent monolayers on both the control and
0.1 mg(Ag) g(scaffold)21 webs (Figs. 3i and 3j,
respectively). As the concentration of Ag within the
PLCL scaffold was increased, the attachment of HEK
was observably decreased after 7 days (Figs. 3g, 3h) as
well as their ability to achieve confluency over the
surface of the scaffolds (Figs. 3k, 3l).
To analyze whether the cells in the scaffolds
remained viable after 7 and 14 days, a Live/Dead cell
viability assay was used. No significant decreases in cell
viability were noted at either time point for the control
or 0.1 mg Ag/g scaffold webs (Figs. 4a, 4b, 4e, 4f). As
shown, nearly all of the cells were viable 7 and 14 days
on both control (Figs. 4a, 4e) and 0.1 mg(Ag) g(scaf-
fold)21 webs (Figs. 4b, 4f). For the 0.5 mg(Ag)
g(scaffolds)21 webs (Figs. 4c, 4g), the presence of dead
cells is readily apparent after 14 days. Moreover, a
decrease in HEK viability was observed by the pre-
sence of dead cells after 7 and 14 days growth for the
1.0 mg(Ag) g(scaffold)21 webs (Figs. 4d, 4h)
(p< 0.05). Additionally for each of the webs, some
cells appear out of focus, confirming cell infiltration
into the scaffold interior.
The HEK proliferation was confirmed using aB
viability assay, and the results are presented in Table 2.
Two-way ANOVA with post hoc analysis revealed
significant differences between scaffolds (p< 0.05) for
both time points. Compared to cells grown as a
monolayer, HEK proliferation was observed to in-
crease to approximately 120% by 7 days and over
200% by 14 days on control PLCL scaffolds. Similar
to the observation of decreased HEK attachment fol-
lowing an increase in Ag concentration, an increase in
Ag content resulted in a decrease in HEK viability
(Table 2). For the 0.1, 0.5, and 1.0 mg(Ag) g(scaf-
folds)21 the proliferation of HEK was approximately
110, 100, and 75% for 7 days, respectively, and 210,
150, and 100% by 14 days, respectively. Despite the
decreasing trend, the greater than 100% proliferation
is indicative of HEK growth along the increased sur-
face area provided by the three-dimensional structure
of the webs, compared to monolayer growth.
Mechanical Properties
The addition of Ag-nps altered the mechanical
properties of the PLCL scaffold at 14 days of cell
culture and 7 days of in vitro enzymatic degradation
(Fig. 5). Uniaxial tensile tests of the PLCL scaffolds
revealed a statistically significant (p< 0.001) decrease
in the modulus of elasticity (E) values for 0.1 mg(Ag)
g(scaffold)21 webs (1.14 MPa), 0.5 mg(Ag) g(scaf-
fold)21 webs (1.08 MPa), and 1.0 mg(Ag) g(scaf-
fold)21 webs (1.03 MPa) compared to the PLCL
control (1.78 MPa) for all treatments. Growth of cells
on the scaffolds for 14 days was shown to significantly
increase (p< 0.001) E for each of the PLCL scaffolds
(1.66, 1.53, and 1.27 MPa for the 0.1, 0.5, and
1.0 mg(Ag) g(scaffold)21 webs, respectively, compared
to the acellular treatment group. Not surprisingly,
in vitro enzymatic degradation of the scaffolds was
associated with a statistically significant (p< 0.001)
decrease in the modulus of elasticity for each of the 0.1,
0.5 and 1.0 mg(Ag) g(scaffolds)21 (0.94, 0.88,
0.83 MPa, respectively), compared to the 0.0 mg(Ag)
g(scaffolds)21 (1.45 MPa).
FIGURE 4. Fluorescent images of HEK after 7 and 14 days
on PLCL scaffolds, proliferation assessed using Live/Dead
assay. (a) 0 mg(Ag) g(scaffold)21, 7 days; (b) 0.1 mg(Ag)
g(scaffold)21, 7 days; (c) 0.5 mg(Ag) g(scaffold)21, 7 days; (d)
1.0 mg(Ag) g(scaffold)21, 7 days; (e) 0.0 mg(Ag) g(scaffold)21,
14 days; (f) 0.1 mg(Ag) g(scaffold)21, 14 days; (g) 0.5 mg(Ag)
g(scaffold)21, 14 days; (h) 1.0 mg(Ag) g(scaffold)21, 14 days.
Live cells stain green and dead cells stain red. Magnification
of 103 for all images.
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Antibacterial Efficacy
The 20 nm Ag-nps alone were shown to inhibit the
growth of S. aureus and E. coliMG1655. The MIC and
MBC values for each strain were found to be 32.0 and
32.0 lg mL21 for S. aureus, whereas the MIC and
MBC was 64.0 and 85.3 lg mL21 for E. coli (Table 3).
The control and 0.1 mg(Ag) g(scaffolds)21 were not
shown to inhibit bacterial growth, while the 0.5 and
1.0(Ag) g(scaffolds)21 were shown to minimally and
substantially inhibit the growth of both bacterial
strains (Figs. 6a, 6b). Exposure to in vitro enzymatic
degradation was performed to mimic accelerated
in vivo degradation and allow for the release of anti-
microbial Ag-nps and Ag ions. Degradation for 7 days
caused a loss in mass of 40.9% for the control PLCL
scaffold, compared to 37.6, 39.1, and 36.9% for the
0.1, 0.5, and 1.0 mg(Ag) g(scaffolds)21, respectively.
ICP-MS analysis showed that the Ag content in the
scaffolds before and after degradation treatment re-
mained constant, implying uniform degradation of the
scaffolds and release of Ag-nps. Following 7 days
degradation, the Ag content of the 0.1, 0.5, and
1.0 mg(Ag) g(scaffolds)21 scaffolds was 0.11 ± 0.02,
0.49 ± 0.02, and 1.11 ± 0.00 mg(Ag) g(scaffold)21,
respectively. However, the amount of Ag-nps released
from the PLCL scaffold into the KGM-2 medium or
the enzymatic degradation solution was sufficient only
at the highest concentration of 1.0 mg(Ag) g(scaf-
folds)21 to impart antibacterial efficacy against either
of the bacterial strains tested.
DISCUSSION
In recent years, interest has grown for the utilization
of Ag-nps rather than traditional antibiotics due to
their broad antimicrobial activity against both Gram-
negative and Gram-positive bacteria, including multi-
drug-resistant strains.27,28 The application of Ag-nps in
tissue engineered scaffolds for skin regeneration is
pivotal in the reduction of infection that is rampant
particularly in burn wounds. Many successful and
promising attempts have been made to incorporate
Ag-nps into biomaterials for continuous release to
impart antibacterial activity including nanoparticulate
Ag bone cement1 and titanium implants coated with a
silver-hydroxyapatite layer.4 Attempts have also been
made to investigate the feasibility of the incorporation
of Ag-nps into polymer scaffolds for various antimi-
crobial applications.8,11
However, before the scaffold is used for in vivo tissue
engineering, it is essential to identify an optimum
concentration of released Ag-nps that would show
antimicrobial activity without having any cytotoxic
effect on the cells of the targeted tissue. Additionally, it
has been reported that Ag-nps of various sizes can
cause toxicity to various human cell lines in vitro, and
it was therefore important to limit the concentration of
the Ag-nps incorporated into PLCL scaffolds in this
study.19,24
The present study highlights the usefulness of
incorporating 20 nm Ag-nps into electrospun PLCL
scaffolds in order to both foster the growth of HEK,
and to ideally impart some level of antimicrobial
activity through the protracted release of Ag-nps into
the culture medium. This was achieved through the
fabrication of PLCL scaffolds that incorporated
Ag-nps, and was based upon the established elec-
trospinning parameters developed in our laboratory.5
It was confirmed by TEM that the 20 nm Ag-nps
were well incorporated within the fibers. While HEK
exposed to the 20 nm Ag-nps alone caused a significant
FIGURE 5. Modulus of elasticity (E) for PLCL scaffolds
under uniaxial tensile stress. All data is expressed as
mean 6 standard error of the mean (MPa). * Denotes statisti-
cal difference (p < 0.001) between 0 mg(Ag) g(scaffold)21 and
all other scaffolds for each treatment set; # denotes additional
statistical difference (p < 0.001) between 1.0 mg(Ag) g(scaf-
fold)21 and all other scaffolds for 14 days cellular growth
treatments.





7 days 14 days
0.0 mg(Ag) g21 50:50 PLCL scaffold 124.5 ± 0.5 223.1 ± 1.4
0.1 mg(Ag) g21 50:50 PLCL scaffold 112.6 ± 0.4 213.9 ± 2.7
0.5 mg(Ag) g21 50:50 PLCL scaffold 98.3 ± 1.8 150.2 ± 5.2
1.0 mg(Ag) g21 50:50 PLCL scaffold 75.9 ± 2.4 102.0 ± 1.1
All data is expressed as mean ± standard error of the mean. Two-
way ANOVA with post hoc analysis revealed significant differences
between each scaffold (p < 0.05) for both time points.
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decrease in viability starting at 50 lg mL21, their
incorporation into the PLCL scaffold only resulted
in a substantial decrease in cell viability for the
highest Ag concentration of 1.0 mg(Ag) g(scaf-
folds)21 webs. In fact, the HEK flourished on and
within the majority of the scaffolds after 7 and
14 days of culture. The morphologic observations of
cell behavior on the nanofiber scaffolds confirmed
that HEK proliferated well on the Ag-nps containing
nanofibers as monolayer cultures. Additionally, the
range in modulus of elasticity of 0.83–1.78 MPa for
the Ag-nps containing PLCL scaffolds compares well
to that found by an electrospun PLCL scaffold of
similar dimensions by others (0.8 MPa).16
The antibacterial results for the 20 nm Ag-nps
alone are congruent with our previous studies for
20 nm Ag-nps stabilized in a phosphate buffer.27 An
initial antibacterial efficacy test of Ag-np incorpo-
rated scaffolds was performed by placing uniform
disks of each scaffold onto bacterial lawns and into
bacterial broths. It was observed that the scaffold
could not deliver overnight or 24 h inhibition of
bacterial growth, likely due to the slow release of Ag
from the scaffolds over time. Therefore, enzymatic
degradation of the scaffolds was conducted in order
to simulate the protracted release of Ag. Based on the
bacterial inhibition results of released Ag, it can be
concluded that at least a 0.5 mg(Ag) g(scaffolds)21 is
necessary to inhibit both Gram-positive and Gram-
negative bacterial growth. However, this result also
highlights the necessity for combination therapies, in
order to deliver an immediate antimicrobial to the
wound site. A potential method could employ a
coating of Ag-nps onto the scaffold surface at a
concentration less than 100 lg mL21 (Table 3).
This study sought to use electrospinning to fabricate a
novel antibacterial skin scaffoldingmaterial composed of
PLCL degradable copolymer incorporated with Ag-nps.
The potential use of the electrospun Ag-nps PLCL scaf-
fold for skin regeneration was evaluated in vitro with
HEK using models for cell attachment, proliferation and
viability, with Gram-positive and Gram-negative bacte-
rial strains for antibacterial efficacy, and a uniaxial tensile
test for biomaterialmechanical properties. In conclusion,
PLCL is a suitable choice for soft tissue scaffolds since it is
biocompatible, facilitates rapid attachment and growth
of cells, and has a lowmodulus of elasticity similar to that
of human skin. These results showed that the release of
Ag content was sufficient to inhibit bacterial growth at a
scaffold concentration between 0.5 and 1.0 mg(Ag)
g(scaffolds)21. Additionally, these scaffolds supported
the robust attachment and proliferation of keratinocytes
FIGURE 6. Antibacterial efficacy of PLCL scaffolds incorporated with 0.0 (‘‘0’’), 0.1 (‘‘13’’), 0.5 (‘‘53’’), and 1.0 (‘‘103’’) mg(Ag)
g(scaffold)21. (a) Staphylococcus aureus (ATCC 25213), (b) Escherichia coli (MG1655).
TABLE 3. Minimal inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC).
Bacterial strain
AgNO3 20 nm Ag-nps
MIC (lg/mL) MBC (lg/mL) MIC (lg/mL) MBC (lg/mL)
S. aureus 2 4 32 32
E. coli 2 2 64 85.3
The data are expressed as means. All standard errors of the means were zero.
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on the scaffold, while maintaining sufficient mechanical
properties to warrant skin implantation.
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